Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection

NCT02555293 is registered in ClinicalTrials.gov with RWTH Aachen University as lead sponsor.

NCT NCT02555293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02555293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection
Lead sponsor
RWTH Aachen University
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2016
Completion date
November 20, 2020
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major liver resection, malignant liver disease